VEGFR-Fc fusion protein formulations
Protein formulations and methods of making and using such formulations are provided herein. The formulation can be an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the formulation comprises a VEGFR-Fc fusion protein, such as aflibercept.
1. A formulation comprising: (a) aflibercept;
(b) 5% (w/v) sucrose; and
(c) trehalose;
wherein the formulation does not comprise a buffer; wherein the pH is between 5.0 and 6.8; wherein the pH remains within 0.3 pH units of the starting pH after two weeks of storage at 40° C.; and wherein the formulation is formulated for intravitreal administration.
2. The formulation of claim 1 , wherein the pH is about 5.2, about 5.5, about 5.8, about 6.0, about 6.2, about 6.3, about 6.4, or about 6.5.
3. The formulation of claim 1 , wherein the concentration of aflibercept is about 40 mg/ml.
4. The formulation of claim 1 , wherein the concentration of trehalose is between 2% and 10% (w/v).
5. The formulation of claim 1 , wherein the concentration of trehalose about 3.5%, or about 5% (w/v).
6. The formulation of claim 1 , wherein the total concentration of sucrose and trehalose is about 8.5%, or about 10% (w/v).
7. The formulation of claim 1 , further comprising a surfactant.
8. The formulation of claim 7 , wherein the surfactant is polysorbate 20, polysorbate 80 or poloxamer 188.
9. The formulation of claim 7 , wherein the concentration of the surfactant is between 0.001 and 0.1%.
10. The formulation of claim 1 , further comprising a tonicity agent.
11. The formulation of claim 10 , wherein the tonicity agent is sodium chloride or potassium chloride.
12. The formulation of claim 11 , wherein the concentration of the tonicity agent is between 1 mM and 150 mM.